Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 15/20 | 0.51 |
| ▸ | NR1I2 | O75469 | 5/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4147810 | 0.88 | CASR (0.56) | CASRNR1I2ALDH1A1LMNACYP1A2 | |
| SCHEMBL4138510 | 0.86 | CASR (0.67) | CASRNR1I2ALDH1A1LMNACYP1A2 | |
| SCHEMBL4143854 | 0.85 | CASR (0.65) | CASRNR1I2 | |
| SCHEMBL4138096 | 0.85 | CASR (0.69) | CASRNR1I2ALDH1A1LMNACYP1A2 | |
| SCHEMBL27751195 | 0.85 | CASR (0.52) | CASRNR1I2 | |
| SCHEMBL4135738 | 0.84 | CASR (0.49) | CASRNR1I2ALDH1A1LMNACYP1A2 | |
| SCHEMBL4142850 | 0.83 | NR1I2 (0.70) | CASRNR1I2ALDH1A1LMNACYP1A2 | |
| SCHEMBL4142963 | 0.82 | CASR (0.57) | CASRNR1I2ALDH1A1LMNACYP1A2 | |
| SCHEMBL4143278 | 0.81 | CASR (0.54) | CASRNR1I2ALDH1A1LMNACYP1A2 | |
| SCHEMBL4147873 | 0.81 | CASR (0.77) | CASRNR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137557-A1 | Calcilytic Compounds | SMITHKLINE BEECHAM CORPORATION | 2009-05-28 | — | — | US | disclosed |
| EP-1951244-A2 | CALCILYTIC COMPOUNDS | SmithKline Beecham Corporation (US) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007062370-A2 | CALCILYTIC COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137557-A1 | Calcilytic Compounds | CALCR, SOST, CALCB | CASR 12/4885NR1I2 3373/4885ALDH1A1 4674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.